From Linear ‘Dogma‘ and Trastuzumab–emtansine to Future Transcriptional Circuitry-Based Drug Discovery for Breast Cancer

Future Oncology - United Kingdom
doi 10.2217/fon.13.252
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Medicine Ltd

Related search

Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

Novel Approaches to Target HER2-positive Breast Cancer: Trastuzumab Emtansine

Cancer Management and Research
Oncology
2016English

Drug Discovery for Breast Cancer and Co-Instantaneous Cardiovascular Disease: What Is the Future?

Future Medicinal Chemistry
Drug DiscoveryMolecular MedicinePharmacology
2013English

Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab With Taxane for Human Epidermal Growth Factor Receptor 2–positive Advanced Breast Cancer: Final Results From MARIANNE

Cancer
Cancer ResearchOncology
2019English

Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis

Frontiers in Microbiology
Microbiology
2018English

Personalized Drug Combinations to Overcome Trastuzumab Resistance in HER2-positive Breast Cancer

Biochimica et Biophysica Acta - Reviews on Cancer
Cancer ResearchOncologyGenetics
2014English

A Drug Discovery Partnership for Personalized Breast Cancer Therapy

2013English

Trastuzumab-Resistance and Breast Cancer

2011English

Substituting Adjuvant Trastuzumab Emtansine for Herceptin Improves Survival in Patients With Human Epidermal Growth Factor Receptor 2–positive Breast Cancer

Cancer
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy